Molecular characterization of dipeptidyl peptidase activity in serum -: Soluble CD26/dipeptidyl peptidase IV is responsible for the release of X-Pro dipeptides

被引:234
作者
Durinx, C
Lambeir, AM
Bosmans, E
Falmagne, JB
Berghmans, R
Haemers, A
Scharpé, S
De Meester, I
机构
[1] Univ Antwerp, Dept Pharmaceut Sci, B-2610 Antwerp, Belgium
[2] Eurogenet, Tessenderlo, Belgium
来源
EUROPEAN JOURNAL OF BIOCHEMISTRY | 2000年 / 267卷 / 17期
关键词
attractin; dipeptidyl peptidase IV; CD26; serum protease; type; 2; diabetes;
D O I
10.1046/j.1432-1327.2000.01634.x
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Dipeptidyl peptidase IV (DPPIV, EC 3.4.14.5) is a serine type protease with an important modulatory activity on a number of chemokines, neuropeptides and peptide hormones. It is also known as CD26 or adenosine deaminase (ADA; EC 3.5.4.4) binding protein. DPPIV has been demonstrated on the plasmamembranes of T cells and activated natural killer or B cells as well as on a number of endothelial and differentiated epithelial cells. A soluble form of CD26/DPPIV has been described in serum. Over the past few years, several related enzymes with similar dipeptidyl peptidase activity have been discovered, raising questions on the molecular origin(s) of serum dipeptidyl peptidase activity. Among them attractin, the human orthologue of the mouse mahogany protein, was postulated to be responsible for the majority of the DPPIV-like activity in serum. Using ADA-affinity chromatography, it is shown here that 95% of the serum dipeptidyl peptidase activity is associated with a protein with ADA-binding properties. The natural protein was purified in milligram quantities, allowing molecular characterization (N-terminal sequence, glycosylation type, CD-spectrum, pH and thermal stability) and comparison with CD26/DPPIV from other sources. The purified serum enzyme was confirmed as CD26.
引用
收藏
页码:5608 / 5613
页数:6
相关论文
共 47 条
  • [21] Inhibition of the activity of dipeptidyl peptidase IV as a treatment for type 2 diabetes
    Holst, JJ
    Deacon, CF
    [J]. DIABETES, 1998, 47 (11) : 1663 - 1670
  • [22] The adenosine deaminase-binding region is distinct from major anti-CD26 mAb epitopes on the human dipeptidyl peptidase IV(CD26) molecule
    Hühn, J
    Olek, S
    Fleischer, B
    von Bonin, A
    [J]. CELLULAR IMMUNOLOGY, 1999, 192 (01) : 33 - 40
  • [23] Dipeptidyl peptidase IV from human serum: Purification, characterization, and N-terminal amino acid sequence
    Iwaki-Egawa, S
    Watanabe, Y
    Kikuya, Y
    Fujimoto, Y
    [J]. JOURNAL OF BIOCHEMISTRY, 1998, 124 (02) : 428 - 433
  • [24] The mahogany mouse mutation - further links between pigmentation, obesity and the immune system
    Jackson, IJ
    [J]. TRENDS IN GENETICS, 1999, 15 (11) : 429 - 431
  • [25] Dipeptidyl-peptidase IV-beta, a novel form of cell-surface-expressed protein with dipeptidyl-peptidase IV activity
    Jacotot, E
    Callebaut, C
    Blanco, J
    Krust, B
    Neubert, K
    Barth, A
    Hovanessian, AG
    [J]. EUROPEAN JOURNAL OF BIOCHEMISTRY, 1996, 239 (02): : 248 - 258
  • [26] Kähne T, 1999, INT J MOL MED, V4, P3
  • [27] DEGRADATION OF GLUCOSE-DEPENDENT INSULINOTROPIC POLYPEPTIDE AND TRUNCATED GLUCAGON-LIKE PEPTIDE-1 IN-VITRO AND IN-VIVO BY DIPEPTIDYL PEPTIDASE-IV
    KIEFFER, TJ
    MCINTOSH, CHS
    PEDERSON, RA
    [J]. ENDOCRINOLOGY, 1995, 136 (08) : 3585 - 3596
  • [28] Lamborn C, 1997, LAB ANIMAL, V26, P26
  • [29] PROTEINS OF THE KIDNEY MICROVILLAR MEMBRANE - AMPHIPATHIC FORM OF DIPEPTIDYL PEPTIDASE-IV
    MACNAIR, RDC
    KENNY, AJ
    [J]. BIOCHEMICAL JOURNAL, 1979, 179 (02) : 379 - +
  • [30] Enhanced insulin secretion and improved glucose tolerance in mice lacking CD26
    Marguet, D
    Baggio, L
    Kobayashi, T
    Bernard, AM
    Pierres, M
    Nielsen, PF
    Ribel, U
    Watanabe, T
    Drucker, DJ
    Wagtmann, N
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2000, 97 (12) : 6874 - 6879